The FDA has approved pembrolizumab immunotherapy, the first treatment to lower kidney cancer recurrence risk after surgery. UT Southwestern helps patients explore its benefits and risks.
A new immunotherapy drug combination has been dubbed a significant advancement in kidney cancer treatment. The combination of ipilimumab and nivolumab can improve outcomes and quality of life. Learn more.
Hans Hammers, M.D., Ph.D. /
James Brugarolas, M.D., Ph.D.
When patients are diagnosed with stage 4 kidney cancer, they have only a 1-in-10 chance of survival. At UT Southwestern’s Kidney Cancer Program, the odds are substantially higher.
Hans Hammers, M.D., Ph.D. /
James Brugarolas, M.D., Ph.D.
